Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Dilutive issuance
confidence 95%
filed 2026-05-27
HWH International entered into a Securities Purchase Agreement on May 27, 2026 to sell 20 million shares of common stock and warrants to purchase 160 million additional shares to Smart Dynamics Technology Limited for $10 million. The filing explicitly discloses this as an unregistered sale under Item 3.02, relying on Section 4(a)(2) and Regulation D exemptions. The transaction grants the purchaser anti-dilution rights and board appointment rights, indicating significant dilution and control implications for existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-27
Item 3.02
Wheeler Real Estate Investment Trust issued 757,850 shares of common stock in exchange for preferred stock held by existing investors. This is a classic unregistered equity issuance under Section 3(a)(9) of the Securities Act, disclosed under Item 3.02. The transaction is dilutive to existing common shareholders and material to investor assessment of capital structure and ownership, even though no cash proceeds were received and preferred shares were retired.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-27
Item 1.01
Artelo Biosciences entered into an At-The-Market (ATM) Offering Agreement on May 26, 2026, authorizing the sale of up to $6,530,000 of common stock through H.C. Wainwright & Co. under an effective Form S-3 shelf registration.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-27
Item 3.02
Carlyle Credit Solutions issued 637 shares of Class I common stock for $0.01 million in an unregistered private placement pursuant to Section 4(a)(2) and Regulation D.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-27
Item 1.01
Data Storage Corp entered into an Equity Distribution Agreement with Maxim Group LLC on May 26, 2026, permitting the Company to offer and sell shares of common stock from time to time through an "at the market" offering mechanism. This is a classic ATM offering arrangement under Rule 415, allowing the Company to raise up to $10,600,000 through dilutive equity issuances. The agreement grants Maxim a 2.5% commission on gross proceeds, and the Company retains discretion over timing, price, and volume of sales, making this a material capital-raising activity that would affect investor assessment of dilution risk.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-27
Item 3.02
The filing discloses an unregistered sale of equity securities totaling approximately $194.8 million across three share classes (Class I, S, and D) on May 1, 2026, exempt under Section 4(a)(2) and Regulations D and S. This is a classic dilutive private placement. The materiality is underscored by the substantial aggregate consideration and the disclosure that the company has raised approximately $7.0 billion cumulatively since inception through such continuous private offerings, indicating this is a significant capital-raising mechanism for the registrant.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-27
Item 3.02
The filing discloses an unregistered sale of equity securities totaling approximately $205.4 million across multiple share classes (Class I, U, D, and S shares) to investors under Section 4(a)(2) and Regulations D and S. This is a classic dilutive issuance under Item 3.02, representing a material capital raise for the company since inception in August 2023 (cumulative ~$9.8 billion in share sales). The transaction is material to investors as it affects ownership dilution and the company's capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-27
Item 3.02
VistaOne, L.P. sold approximately $23.6 million in unregistered limited partnership units across three classes (B, I, and S) to third-party investors as part of a continuous private offering, exempt under Section 4(a)(2) and Regulation D.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-26
Item 8.01
The filing discloses a common stock purchase agreement with White Lion Capital LLC for up to $15.0 million in equity financing, with actual purchases of 7,500 shares totaling $15,650 completed as of May 22, 2026. This represents a dilutive issuance of common stock under a committed purchase arrangement, which is material to investors assessing the registrant's capital structure and ownership dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-05-26
Item 1.01
Starwood Property Trust closed a $600 million private offering of 6.125% senior notes due 2031 on May 26, 2026, under an indenture with The Bank of New York Mellon. The proceeds were used for refinancing existing debt and funding green/social projects, representing a material capital structure change.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 90%
filed 2026-05-26
Item 1.01
Editas Medicine entered into an underwriting agreement on May 26, 2026 to conduct a public offering of 55,555,556 shares of common stock at $2.25 per share, together with accompanying warrants, generating approximately $117.0 million in net proceeds. The offering, which will fund operations into H2 2028, represents a material registered public offering that will dilute existing shareholders, with the warrant component potentially generating an additional $192.5 million upon exercise.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-26
Item 8.01
The filing discloses an At The Market (ATM) Offering Agreement entered into on March 10, 2025, permitting Traws Pharma to offer and sell up to $3,128,399 of common stock shares through Citizens JMP Securities under an effective shelf registration statement. ATM offerings are unregistered equity issuances that are dilutive to existing shareholders and typically signal capital-raising activity at small- and mid-cap issuers; this disclosure is material to investor assessment of equity dilution and the company's liquidity position.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-26
Item 3.02
BlackRock Private Credit Fund disclosed an unregistered sale of 376,795.093 Institutional Class Shares for $8.9 million to feeder vehicles, exempt under Section 4(a)(2) and Regulation S, increasing share count and diluting existing shareholders' ownership interests.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-26
Item 3.02
Goldman Sachs Private Credit Corp. completed an unregistered sale of approximately $84.2 million in Class I and Class S shares to accredited investors and non-U.S. persons, exempt under Section 4(a)(2), Regulation D, and/or Regulation S.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 45%
filed 2026-05-26
Item 7.01
The filing discloses a $900 million private offering of senior secured notes by a subsidiary, with proceeds intended to fund the Klöckner Acquisition and refinance existing debt. While the notes are debt rather than equity, the offering is material and raises capital for a major acquisition. However, this is primarily a debt financing announcement in connection with M&A activity, which may be better classified as ma_activity given the central role of the Klöckner Acquisition in the disclosure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-26
Item 3.02
Apollo Infrastructure Co LLC completed unregistered sales of equity securities totaling approximately $34.6 million across multiple share classes (Series I and Series II A-II, F-I, E, and I shares) to third-party investors under Section 4(a)(2) and Regulations D and S.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-26
Item 1.01
Assembly Biosciences completed a registered public offering of 3,358,602 shares of common stock at $26.50 per share, plus pre-funded warrants to purchase 415,000 additional shares, raising approximately $107.4 million in net proceeds. Underwriters exercised their 30-day option to purchase 566,040 additional shares in full, further diluting existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-26
Item 1.01
Shimmick Corporation entered into an Underwriting Agreement on May 22, 2026, for a public offering of 3,730,000 shares at $3.50 per share, with the underwriter exercising its option to purchase an additional 559,500 shares, resulting in total issuance of 4,289,500 shares and net proceeds of approximately $14.0 million. This is a material equity issuance that dilutes existing shareholders and represents a significant capital raise disclosed under Item 1.01.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-26
Item 3.02
Fortress Private Lending Fund sold 431,701 Class I common shares for $10.4 million in aggregate consideration to accredited investors pursuant to Section 4(a)(2) and Regulation D exemptions, diluting existing shareholders and raising capital.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-05-26
The filing discloses Pre-Paid Purchase #3, a material transaction under Item 1.01 in which Future FinTech issued a Pre-Paid Instrument with a principal amount of $2,160,000 in exchange for $2,000,000 in cash proceeds. This represents a dilutive equity issuance under a pre-paid securities purchase agreement previously approved by shareholders. The transaction is part of a larger $10 million funding facility and involves the issuance of common stock, making it a material capital raise typical of dilutive issuances at smaller-cap companies.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 94%
filed 2026-05-26
Item 1.01
Toppoint Holdings completed a private placement of 5,000,000 shares of common stock at $0.83 per share for aggregate gross proceeds of $4,150,000, structured as a Securities Purchase Agreement with accredited investors and offshore participants under Section 4(a)(2) and Regulation D Rule 506(b). This unregistered equity issuance materially dilutes existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-26
Item 3.02
BurTech completed an unregistered private placement of 252,000 units at $10.00 per unit for $2.52 million in gross proceeds, with 222,000 units sold to the Sponsor and 30,000 to third-party investors, pursuant to Section 4(a)(2) exemption and occurring simultaneously with the IPO.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 72%
filed 2026-05-26
Item 1.01
LiqTech issued $1.1 million in promissory notes to affiliates of Bleichroeder L.P. and Laurence W. Lytton pursuant to a note purchase agreement. The unregistered debt issuance, structured with escalating interest rates (10% rising to 16%) and a short two-month maturity, signals distressed financing typical of small-cap companies under liquidity pressure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-05-26
Item 3.02
Transocean completed an unregistered sale of equity securities, with charter amendments approved by shareholders to authorize issuance of up to 240.8 million shares and 100 million treasury shares, reflecting a material dilutive capital structure change.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-26
Item 3.02
Cartesian Therapeutics disclosed an unregistered sale of equity securities in the form of conversion shares underlying the Term Loans, to be issued in reliance on Section 4(a)(2) and Rule 506(b) of Regulation D. This convertible debt structure will materially affect shareholder equity and voting power.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-26
Item 3.02
The filing discloses an unregistered sale of 7,000 shares of Series C Convertible Preferred Stock for $6,990,000 completed on May 20, 2026, under Section 4(a)(2) and Regulation D Rule 506(b). The preferred shares are convertible into common stock, making this a dilutive equity issuance. The substantial purchase price and convertible nature of the securities indicate material capital raising activity typical of Item 3.02 disclosures.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-26
Item 3.02 discloses an unregistered sale of 11,364 common shares of beneficial interest for approximately $0.3 million at $23.32 per share, exempt under Section 4(a)(2) and Regulation D Rule 506. This is a private placement of equity securities that dilutes existing shareholders and is material to investors assessing the fund's capital structure and share count.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-05-26
Item 1.01
Senti Biosciences issued $10.0 million in Senior Secured Convertible Notes to Celadon Partners SPV 24 on May 20, 2026, pursuant to a Securities Purchase Agreement. The convertible notes are dilutive securities that can convert to equity, materially affecting shareholder equity and voting power.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-26
Item 8.01
Lincoln International completed an initial public offering of 24,207,486 shares of Class A common stock at $20.00 per share, generating gross proceeds of $473.7 million, and issued approximately 81 million shares of Class B and Class C common stock to existing and controlling partners under Section 4(a)(2) exemption, materially diluting existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-26
Item 1.01
Nocera entered into an Equity Purchase Facility Agreement on May 22, 2026, granting an institutional investor the right to purchase up to $100 million in newly issued common stock over a 24 months, issued in reliance on Section 4(a)(2) of the Securities Act. The transaction is subject to a 19.99% Exchange Cap absent stockholder approval and represents a material capital-raising transaction that will significantly affect shareholder equity and voting power.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-05-26
Item 8.01
Rhinebeck Bancorp announced a public offering of 8,912,500 shares at $10.00 per share in connection with conversion from a mutual holding company to a fully stock holding company. This is a material dilutive equity issuance that would significantly affect shareholder ownership and the company's capital structure, warranting disclosure under Item 8.01.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-26
Item 3.02
Blue Owl Credit Income Corp. completed an unregistered private placement of 117,762 shares of Class I common stock to feeder vehicles on May 1, 2026, for approximately $1.08 million, exempt under Section 4(a)(2) and Regulation S.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-26
Item 3.02
Blue Owl Technology Income Corp. completed an unregistered sale of 255,168 shares of Class I common stock for approximately $2.51 million as of May 1, 2026, exempt under Section 4(a)(2) and Regulation S.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-26
Item 3.02
The filing discloses an unregistered sale of 382,995 common shares for $10,000,000 pursuant to Section 4(a)(2) and Regulation D/S under the Securities Act. This is a classic dilutive issuance of equity securities in a private placement, which materially affects existing shareholders' ownership percentages and is a significant capital-raising event for the fund.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-26
Item 3.02
Carlyle Private Equity Partners Fund completed an unregistered sale of limited partnership units totaling approximately $9.3 million across three classes (E-A, E-I, and C) on May 1, 2026, exempt under Section 4(a)(2) and Regulation D.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-26
Item 3.02
Golub Capital Private Income Fund S issued 11,570 common shares of beneficial interest as of May 1, 2026, pursuant to subscription agreements and exempt under Section 4(a)(2), Regulation D, and/or Regulation S, raising approximately $279,650 in consideration.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-26
Item 3.02
The Fund issued 87,386 common shares of beneficial interest for $2,116,500 as of May 1, 2026, pursuant to subscription agreements and exempt under Section 4(a)(2), Regulation D, and/or Regulation S.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-22
Item 1.01
Starfighters Space entered into a securities purchase agreement on May 22, 2026, to issue 5,223,879 shares of common stock in a private placement at $3.35 per share, generating approximately $17.5 million in gross proceeds under Section 4(a)(2) and Regulation D Rule 506(b) to accredited investors and qualified institutional buyers.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 68%
filed 2026-05-22
Item 2.03
The Company entered into a $20 million term loan secured by gross proceeds from its at-the-market (ATM) equity offering program, with the lender granted power of attorney to execute equity sales upon default. This financing arrangement directly ties the Company's ability to raise equity capital to debt repayment and creates a dilutive equity issuance mechanism, with the lender able to force equity sales at specified pricing upon default.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-05-22
Item 8.01
The Company issued 3,277,438 shares of Class A common stock on May 22, 2026, in satisfaction of contingent consideration obligations under the Business Combination Agreement. This represents a dilutive issuance tied to a prior M&A transaction (the 2021 business combination with Legacy Navitas), with additional contingent shares (up to 10,000,000 total) potentially issuable if stock price targets are met before October 2026. The disclosure of actual share issuance and the magnitude of contingent consideration makes this material to investors assessing ownership dilution and future capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-22
Item 1.01
Anteris Technologies entered into a Sales Agreement with TD Cowen authorizing an "at the market" offering of up to $250 million in common stock. This is a dilutive equity issuance that would materially affect existing shareholders through potential dilution. The filing explicitly describes the offering structure, commission terms, and use of proceeds for product development, which are hallmarks of a material capital raise disclosed under Item 1.01.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-05-22
Item 8.01
Chase Issuance Trust entered into underwriting and terms agreements on May 21, 2026 for the issuance of $1.25 billion in Class A(2026-1) CHASEseries Notes, with closing expected May 28, 2026. While this is a debt issuance rather than equity, the structured finance nature (asset-backed securities backed by credit card receivables) and the material size ($1.25B) make this a significant capital-raising event. The filing discloses the underwriting agreement, tax opinion, and depositor certification typical of ABS offerings. This is classified as dilutive_issuance as the closest match, though it is technically a debt offering rather than equity; alternatively, this could be other_material as a significant structured finance transaction.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-22
Item 8.01
American Healthcare REIT closed a public offering of 14,000,000 shares of common stock on May 22, 2026, with an additional 2,100,000 shares available under an underwriter option. The filing discloses a forward sale agreement structure where shares were borrowed and sold to hedge the forward purchaser's obligations, with settlement expected by May 20, 2028. This is a material equity issuance that will dilute existing shareholders and raise capital for general corporate purposes and potential investments.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 94%
filed 2026-05-22
Item 1.01
Akamai completed a $3.5 billion convertible note offering ($1.75 billion 2030 Notes and $1.75 billion 2032 Notes) in a private placement under Rule 144A and Section 4(a)(2), with conversion rates of 4.9650 and 5.2408 shares per $1,000 principal respectively, creating significant dilution potential for existing shareholders. The offering also included warrant transactions with additional dilutive effects if stock price exceeds strike prices.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-05-22
Item 1.01
SiTime completed a $1.35 billion registered public offering of 0% Convertible Senior Notes due 2031 with a conversion rate of 0.9611 shares per $1,000 principal amount. The convertible structure creates significant dilution potential to common shareholders upon conversion, and the proceeds are intended to fund the Renesas acquisition.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-05-22
SunPower entered into a note purchase agreement on May 19, 2026 for issuance of 10.00% Convertible Senior Secured Notes due 2029, issued May 20, 2026. The Notes are convertible into Common Stock at an initial conversion price of approximately $1.64 per share (610.3143 shares per $1,000 principal), with a maximum conversion rate of 884.9557 shares per $1,000 principal following certain corporate events. Item 3.02 explicitly discloses unregistered sales of equity securities under Section 4(a)(2) of the Securities Act. This convertible debt issuance represents a dilutive capital raise with significant equity conversion potential.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-22
Item 1.01
Smart Powerr Corp. entered into a securities purchase agreement on May 19, 2026, to issue 4,500,000 shares of common stock at $0.45 per share in a registered direct offering, raising approximately $2 million in gross proceeds, with a provision for additional closings of up to 4,500,000 more shares at the Purchasers' option.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-22
Item 3.02
Ondas Inc. disclosed unregistered sales of equity securities exempt from registration under Regulation D, representing a material private placement that dilutes existing shareholders and affects the registrant's capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-05-22
The filing discloses multiple closings of convertible promissory notes and warrants under a Note Purchase Agreement with White Lion Capital. The third closing on May 18, 2026 involved issuance of a $555,556 convertible note and warrants to purchase 888,509 shares of common stock. Combined with prior closings totaling approximately $1.6M in convertible notes and 2.6M+ warrant shares, this represents a material dilutive issuance of equity securities. Item 2.03 addresses the creation of direct financial obligations (the convertible notes), while the warrant issuances constitute dilutive equity instruments.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-22
The filing discloses entry into an equity distribution agreement on May 22, 2026, authorizing the issuance and sale of up to $100 million in common units through Morgan Stanley as sales agent via at-the-market offerings. This is a classic dilutive equity issuance that would materially affect existing unitholders' ownership percentages and is a significant capital-raising event for the registrant.
View raw filing on EDGAR →